Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$33.11 USD

33.11
1,040,983

+0.26 (0.79%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $33.13 +0.02 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Idexx Laboratories (IDXX) Tops Q1 Earnings Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 4.85% and 0.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline

by Zacks Equity Research

Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tandem Diabetes (TNDM) Gains From Innovation Amid Macro Issues

by Zacks Equity Research

Tandem Diabetes (TNDM) seeks to grow its business through the acquisition of products or technologies and investments in businesses.

Inari Medical (NARI) Up 4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Inari Medical (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tandem Diabetes (TNDM) Gains From Innovation Amid Competition

by Zacks Equity Research

Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.

Why Is Tandem Diabetes Care (TNDM) Up 27.4% Since Last Earnings Report?

by Zacks Equity Research

Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).

Tandem Diabetes Care, Inc. (TNDM) Surges 9.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Tandem Diabetes (TNDM) Posts Wider Q4 Loss, Gross Margin Down

by Zacks Equity Research

Tandem Diabetes (TNDM) reports a higher-than-expected loss in the fourth quarter of 2023.

Tandem Diabetes Care, Inc. (TNDM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Tandem Diabetes Care, Inc. (TNDM) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -17.39% and 3.94%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Teleflex (TFX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tandem (TNDM) Broadens Insulin Pumps Line in the U.S. With Mobi

by Zacks Equity Research

Tandem's (TNDM) Mobi is claimed to be the world's smallest durable automated insulin delivery system.

Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q4 Earnings Expected to Decline

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

CVRx (CVRX) delivered earnings and revenue surprises of 20% and 3.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Tandem Diabetes (TNDM) and Abbott Debut New Integrated Offering

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system to be integrated with Abbott's Freestyle Libre 2 Plus sensor.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors remain optimistic about Tandem Diabetes (TNDM), backed by the impressive spree of product introductions.

Tandem Diabetes (TNDM) Avails Tandem Source in the United States

by Zacks Equity Research

Tandem Diabetes (TNDM) announces the full U.S. launch of Tandem Source, a new diabetes management platform for customers and healthcare providers.

Tandem Diabetes (TNDM) Launches Dexcom G7 Integrated t:slim X2

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system in the world to feature Dexcom's most advanced CGM technology.

Why Is Tandem Diabetes Care, Inc. (TNDM) Up 33.2% Since Last Earnings Report?

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors remain optimistic about Tandem Diabetes (TNDM), backed by upcoming innovative launches, including Mobi and the new integrated CGM offering.

Tandem Diabetes (TNDM) Posts Wider Q3 Loss, Trims '23 Sales View

by Zacks Equity Research

Tandem Diabetes (TNDM) reports a higher-than-anticipated loss in the third quarter of 2023.

Compared to Estimates, Tandem Diabetes Care, Inc. (TNDM) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Tandem Diabetes Care, Inc. (TNDM) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Urmimala Biswas headshot

MedTech Stocks' Q3 Earnings Due on Nov 1: IDXX, EXAS & More

by Urmimala Biswas

MedTech companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how IDXX, EXAS, TNDM and NVST fare this time.

Analysts Estimate Tandem Diabetes Care, Inc. (TNDM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.